Clinical trials: Gardasil Vaccine, active
Cervical Cancer, Condylomata Acuminata
Plateau Antibody Levels of a Recombinant (E.Coli) HPV Nonavalent Vaccine Versus Gardasil®9 in Young Women
This study is designed to compare plateau antibody levels of a novel recombinant human papillomavirus vaccine (types 6,11,16,18,31,33,45,52,58 )(E.Coli) manufactured by Xiamen Innovax Biotech CO., Ltd., with Gardasil®9 in females…
- Trial name
- NCT06197802
- Testing
- Recombinant Human Papillomavirus Nonavalent (Types 6,11,16,18,31,33,45,52,58 )Vaccine(E.Coli), Gardasil®9
- Where
- China
- Volunteers
- 392 people, healthy volunteers welcome
- Sponsor
- Xiamen University
Human Papillomavirus Infection
Clinical Trial to Assess the Safety, Tolerability, Reactogenicity, and Immunogenicity of a 10 Valent Human Papillomavirus Virus (10vHPV) Vaccine
Human papilloma virus (HPV) is the most common viral infection of the reproductive system and is spread through contact with infected genital skin, mucous membranes, or bodily fluids.
- Trial name
- NCT07888686
- Testing
- 10vHPV, Gardasil9
- Where
- Australia
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- Serum Institute of India Pvt. Ltd.
Immunization, HPV Infection
Comparing Immune Response of 2 vs 3 HPV Doses (27-45 Years Old)
The goal of this clinical trial is to compare a 2-dose and 3-dose series of 9vHPV vaccine among 27-45-year-old females to assess if 2 doses elicit a noninferior immune response.
- Conditions
- Immunization, HPV Infection, Human Papillomavirus
- Trial name
- NCT05672927
- Testing
- 9-valent HPV vaccine, 2 doses alternate timing, 9-valent HPV vaccine, 3 doses standard timing
- Where
- United States
- Volunteers
- 618 people, healthy volunteers welcome
- Sponsor
- The University of Texas Medical Branch, Galveston
Recurrent Respiratory Papillomatosis (RRP)
Efficacy of Booster Injection With Gardasil-9 Vaccine on Intersurgical Interval* for Adults With Recurrent Respiratory Papillomatosis*
The investigators propose the study titled "Efficacy of booster injection with Gardasil-9 vaccine on intersurgical interval (ISI) for adults with recurrent respiratory papillomatosis (RRP)".
- Trial name
- *ISI *RRP (NCT07339163)
- Testing
- GARDASIL®9 (Human Papillomavirus 9-valent Vaccine, Recombinant)
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Ohio State University
Allogeneic Hematopoietic Stem Cell Transplant Recipient, Hematopoietic and Lymphoid Cell Neoplasm
Gardasil 9 Vaccine in Preventing HPV Infection in Patients With Hematologic Malignancies Undergoing Donor Stem Cell Transplant
This phase IV trial studies how well Gardasil 9 vaccine works in preventing human papillomavirus (HPV) infection in patients with hematologic malignancies who are undergoing donor stem cell transplant.
- Trial name
- NCT03023631
- Testing
- Recombinant Human Papillomavirus Nonavalent Vaccine
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- M.D. Anderson Cancer Center
Papillomavirus Infections
Efficacy, Immunogenicity and Safety of V503 in Chinese Women Aged 20-45 Years (V503-023)
This study will evaluate the efficacy, immunogenicity and safety of 9-valent human papillomavirus (9vHPV; V503) vaccine in Chinese women 20 to 45 years of age.
- Trial name
- NCT03998254
- Testing
- V503, Gardasil
- Where
- 6 sites in China
- Volunteers
- 6,000 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Respiratory Recurrent Papillomatosis (RRP), Human Papillomavirus (HPV)
Combination Bevacizumab and PRGN-2012 in Adults With Recurrent Respiratory Papillomatosis (RRP)
Background: Recurrent respiratory papillomatosis (RRP) is a rare disease that causes wart-like growths called papillomas to grow in the airway, most often in the voice box, windpipe, or lungs.
- Conditions
- Respiratory Recurrent Papillomatosis (RRP), Human Papillomavirus (HPV), Papillomavirus Infection, Laryngeal Diseases
- Trial name
- NCT07756840
- Testing
- PRGN-2012, Bevacizumab
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- National Cancer Institute (NCI)
Idiopathic CD4 T Cell Lymphocytopenia
Immunogenicity of the 9-Valent Human Papillomavirus Recombinant Vaccine in People With Idiopathic CD4 T Cell Lymphocytopenia
Background: Diseases related to human papillomavirus (HPV) include warts, lesions, and cancers. ICL is idiopathic CD4 T cell lymphocytopenia. People with this rare disease get more HPV-related diseases than other people do.
- Trial name
- NCT03519464
- Testing
- Gardasil 9
- Where
- United States
- Volunteers
- 54 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Human Papilloma Virus Infection Type 16
Developing a First-void Urine-based Infection Model to Study HPV-specific Antibody-virion Interaction Before and After HPV Vaccination
The current study is an open-label, non-randomized, longitudinal exploratory trial using the licensed Gardasil 9 (9vHPV) vaccine in an off-label context to investigate biological and immunological outcomes in human papillomavirus…
- Trial name
- URVIVE (NCT07407569)
- Testing
- Gardasil 9 (2 dose regimen)
- Where
- 3 sites in Belgium
- Volunteers
- 50 people
- Sponsor
- Universiteit Antwerpen
Human Papilloma Virus, Anal Dysplasia
Evaluating Gardasil HPV Vaccine Humoral and Cellular Immune Responses in People With and Without HIV
This is a phase 2, open-label study to assess the immunogenicity of the 9-valent human papillomavirus (HPV) recombinant vaccine (Gardasil9) in people born male with current or past exposure to androgen blockers or estrogen…
- Conditions
- Human Papilloma Virus, Anal Dysplasia, HIV
- Trial name
- PROTECT (NCT06624839)
- Testing
- Human papillomavirus (HPV) vaccine, 9-valent
- Where
- 2 sites in United States
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- University of Maryland, Baltimore
Vaccine Effectiveness, HPV Vaccination
A Trial to Establish Non-inferiority of Immunogenicity of a Single-dose of CERVAVAC® Quadrivalent HPV Vaccine Compared to the Gardasil® Quadrivalent Vaccine Among Girls and Boys Aged 9 to 14 Years and in Girls/Women Aged 15 to 20 Years in Zambia
The goal of this study is to compare the immune response of the single dose of the CERVAVAC vaccine with the single dose of Gardasil vaccine in girls/women aged 9 to 20 and boys aged 9 to 14 at 6 months, 12 months and 24 months…
- Conditions
- Vaccine Effectiveness, HPV Vaccination, Single Dose, Immunogenicity
- Trial name
- CervALONE (NCT07256912)
- Testing
- quadrivalent HPV vaccine
- Where
- Zambia
- Volunteers
- 1,266 people, healthy volunteers welcome
- Sponsor
- International Agency for Research on Cancer
Chronic Kidney Diseases, Kidney Transplant
Immunogenicity of HPV Vaccine in Transplant Recipients.
To measure levels of HPV antibodies in post-solid-organ transplant recipients who have gotten the HPV9 vaccine.
- Trial name
- NCT05557370
- Testing
- Human Papilloma Virus vaccine (GARDASIL 9)
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Medical College of Wisconsin